• Amylyx Pharmaceuticals reported Q2 2026 results in August, with a net loss of US$43.42 million compared with US$41.44 million a year earlier, and a six‑month net loss of US$84.71 million versus US$77.35 million, even as basic loss per share from continuing operations narrowed slightly year over year.
• The combination of a higher absolute net loss and modest per‑share loss improvement highlights the growing cost base behind Amylyx’s development pipeline at a time when it still generates no revenue.
• Now we’ll examine how this widening Q2 net loss, despite slightly improved loss per share, reshapes Amylyx Pharmaceuticals’ existing investment narrative.

We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Amylyx Pharmaceuticals Investment Narrative Recap

To own Amylyx today, you need to believe that avexitide can become a first treatment for post bariatric hypoglycemia and eventually turn the current zero revenue model into a sustainable business. The Q2 2026 results, with a wider net loss but slightly better loss per share, do not materially change the near term story: the key catalyst is still the LUCIDITY Phase III readout in Q3 2026, while the biggest risk remains continued cash burn without a commercial product.

Among recent company updates, the completion of enrollment and dosing in the pivotal LUCIDITY trial in March 2025 ties most directly to today’s earnings picture. The growing operating expenses reflected in the Q2 2026 loss sit against that upcoming data readout, which could determine whether Amylyx’s current spending on avexitide and broader GLP 1 antagonism eventually translates into its first revenue stream or leaves it as a cash consuming clinical stage business.

Yet behind the improving loss per share, one risk investors should be aware of is the possibility that higher development costs and any delay in avexitide’s path to market could...

Amylyx Pharmaceuticals' narrative projects $168.0 million in revenue and $36.4 million in earnings by 2029. This implies earnings increasing by about $186.5 million from -$150.1 million today.

Uncover how Amylyx Pharmaceuticals' forecasts yield a $25.56 fair value, a 12% upside to its current price.

Exploring Other Perspectives

Before this earnings release, the most optimistic analysts were projecting about US$516.1 million of revenue and roughly US$101.4 million of earnings by 2029, which is a very different story from today’s US$43.42 million quarterly net loss and no revenue. If you lean on those bullish forecasts, you are accepting far more upside in avexitide and the PBH market than the baseline view, and this latest update is a reminder that both those narratives may need to be revisited as new data and spending trends emerge.

Explore 2 other fair value estimates on Amylyx Pharmaceuticals - why the stock might be worth just $25.56!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Amylyx Pharmaceuticals research is our analysis highlighting 2 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Amylyx Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amylyx Pharmaceuticals' overall financial health at a glance.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 52 companies with promising cash flow potential yet trading below their fair value.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 17 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.